AUGUST 10, 2020
Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
AUGUST 03, 2020
Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
